Literature DB >> 18442299

Mechanisms and management of proteinuria in kidney transplant patients.

Azemi A Barama1.   

Abstract

Proteinuria is a common complication occurring after kidney transplantation. It is associated with an increased risk of renal failure and patient death. Treatment with ACE inhibitors or angiotensin receptor antagonists (blockers) has been shown to reduce proteinuria after kidney transplantation, as well as improve both graft and patient survival. An increase in proteinuria has been observed in some patients after initiation of sirolimus therapy. Although the mechanism of this remains unclear, high proteinuria at baseline and poor renal function at baseline have been identified as potential risk factors for the development of proteinuria after conversion to sirolimus. Initiation of sirolimus therapy is not recommended in patients with early histological indicators of glomerular damage; however, in patients with healthy grafts, sirolimus may prevent future glomerulosclerosis. Early treatment with an ACE inhibitor and sirolimus, prior to the appearance of glomerular changes, may result in better outcomes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18442299     DOI: 10.2165/00003495-200868001-00005

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  33 in total

1.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

2.  Angiotensin-converting enzyme inhibition in the prevention and treatment of chronic renal damage in the hypertensive fawn-hooded rat.

Authors:  G H Verseput; A P Provoost; B B Braam; J J Weening; H A Koomans
Journal:  J Am Soc Nephrol       Date:  1997-02       Impact factor: 10.121

3.  Proteinuria following conversion from azathioprine to sirolimus in renal transplant recipients.

Authors:  J M van den Akker; J F M Wetzels; A J Hoitsma
Journal:  Kidney Int       Date:  2006-08-16       Impact factor: 10.612

4.  Sirolimus-associated heavy proteinuria in a renal transplant recipient: evidence for a tubular mechanism.

Authors:  L Straathof-Galema; J F M Wetzels; H B P M Dijkman; E J Steenbergen; L B Hilbrands
Journal:  Am J Transplant       Date:  2006-02       Impact factor: 8.086

5.  Differences in proteinuria and graft function in de novo sirolimus-based vs. calcineurin inhibitor-based immunosuppression in live donor kidney transplantation.

Authors:  Brian R Stephany; Joshua J Augustine; Venkatesh Krishnamurthi; David A Goldfarb; Stuart M Flechner; William E Braun; Donald E Hricik; Vincent W Dennis; Emilio D Poggio
Journal:  Transplantation       Date:  2006-08-15       Impact factor: 4.939

6.  Evolution of proteinuria after conversion from calcineurin inhibitors (CNI) to sirolimus (SRL) in renal transplant patients: a multicenter study.

Authors:  J C Ruiz; F Diekmann; J M Campistol; A Sanchez-Fructuoso; C Rivera; J Oliver; G Fernandez-Fresnedo; M Arias
Journal:  Transplant Proc       Date:  2005-11       Impact factor: 1.066

7.  Proteinuria following a switch from calcineurin inhibitors to sirolimus.

Authors:  Emmanuel Letavernier; Marie-Noëlle Pe'raldi; Antoine Pariente; Emmanuel Morelon; Christophe Legendre
Journal:  Transplantation       Date:  2005-11-15       Impact factor: 4.939

8.  Proteinuria: a new marker of long-term graft and patient survival in kidney transplantation.

Authors:  Gema Fernández-Fresnedo; Juan Jose Plaza; Jaime Sánchez-Plumed; Aurelio Sanz-Guajardo; R Palomar-Fontanet; M Arias
Journal:  Nephrol Dial Transplant       Date:  2004-06       Impact factor: 5.992

9.  Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction.

Authors:  Fritz Diekmann; Klemens Budde; Federico Oppenheimer; Lutz Fritsche; Hans H Neumayer; Josep M Campistol
Journal:  Am J Transplant       Date:  2004-11       Impact factor: 8.086

10.  Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation.

Authors:  Georg Heinze; Christa Mitterbauer; Heinz Regele; Reinhard Kramar; Wolfgang C Winkelmayer; Gary C Curhan; Rainer Oberbauer
Journal:  J Am Soc Nephrol       Date:  2006-02-15       Impact factor: 10.121

View more
  2 in total

Review 1.  Management of nephrotoxicity of chemotherapy and targeted agents: 2020.

Authors:  Varsha Chiruvella; Pavan Annamaraju; Achuta K Guddati
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

Review 2.  Antihypertensive treatment for kidney transplant recipients.

Authors:  Nicholas B Cross; Angela C Webster; Philip Masson; Philip J O'Connell; Jonathan C Craig
Journal:  Cochrane Database Syst Rev       Date:  2009-07-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.